BioScience Laboratories, Inc. and Synomics Pharmaceutical Services Announce Their Partnership to Provide Phase 1 Clinical Study Services

    BOZEMAN, MT, October 10, 2009 /24-7PressRelease/ -- BioScience Laboratories, Inc. and Synomics Pharmaceutical Services announced today their formal partnership to provide a fully integrated phase 1 clinical study capability for trials in healthy human subjects to provide drug manufacturers with a single source for outsourcing clinical trials.

The combination of BioScience Laboratories' 18 years of experience conducting clinical trials and Synomics Pharmaceutical Services' strong reputation for providing pre-clinical and clinical bioanalysis and analytical chemistry services provides drug manufacturers with an outsourcing solution to conduct all aspects of phase 1 clinical trials in a GCP and GLP compliant environment.

In recent years, drug manufacturers have experienced an increased demand on the quality of data from clinical trials. Combined with the drive to decrease the drug development timeline, the industry trend is back towards using contract research organizations located in the United States. To assure FDA acceptance drug manufacturers are requiring, more than ever, clinical trials that are conducted strictly in compliance with the FDA, GCP and GLP guidelines.

For drug manufacturers wanting to realize the revenue of bringing a product to market, it is critical to select a contract research organization that conducts the clinical trial on time, on budget, and with resulting data that is suitable for FDA submission. The partnership between BioScience Laboratories and Synomics Pharmaceutical Services allows a single point of project management with the full array of bioanalytical and clinical trials capabilities.

"Our eighteen years experience in conducting clinical trials combined with Synomics Pharma's reputation for a strong quality system and state-of-the art bioanalytical capabilities is a winning combination as a single source for outsourcing phase 1 clinical trials." - Daryl Paulson, Ph.D., CEO of BioScience Laboratories

"Synomics Pharma's comprehensive quality management system reduces regulatory risk," said John Pirro, Vice President and Chief Operating Officer of Synomics Pharma. "Our active involvement with the Bioanalytical Quality Standards Initiative (BQSI) for the implementation of ICH Q10 for clinical trials demonstrates our commitment to consistency and quality in clinical bioanalysis. The alliance between Synomics Pharma and BioScience Laboratories produces a versatile topical clinical phase I trial service offering that will be highly beneficial to the industry."

BioScience Laboratories, Inc. was founded in 1991 in Bozeman, MT, to provide antimicrobial product testing and result interpretation grounded in science. Bioscience Laboratories Inc. strives to assist its clients in strengthening their current market positions through product testing and aid in the development of new products and new markets. Today, BioScience Laboratories offers a variety of state-of-the-art laboratory services and guidance regarding federal regulatory agency requirements for the healthcare, pharmaceutical, personal care and consumer products markets. For more information about BioScience Laboratories please visit www.biosciencelabs.com.

Synomics Pharmaceutical Services, a leading global Contract Research Organization (CRO), specializes in customized, pre-clinical and clinical bioanalytical services, storage stability services, and analytical chemistry services for the pharmaceutical, personal care, and allied industries. Based in Wareham, Massachusetts, USA, the company's quality system has been globally recognized by authorities as an industry benchmark. For more information about Synomics Pharmaceutical Services, visit www.synomicspharma.com.

# # #